Tech Guruji's video: Trump Wonder Drug Cipla launch Casirivimab Imdevimab MRP-59750

Hey dosto, COVID-19 treatment: Roche, Cipla launch antibody cocktail Casirivimab and Imdevimab in India, costs Rs 59,750. The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate COVID-19 in adults and pediatric patients. As India tackles the second wave of coronavirus, drug major Roche and Cipla launched the first batch of an antibody cocktail on Monday for the treatment of mild to moderate Covid-19 patients who are at high risk. "The first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June," said Cipla and Roche in a joint statement. "The availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalisation, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens," said V Simpson Emmanuel, Managing Director and CEO, Roche Pharma India. Umang Vohra, MD & Global CEO Cipla said the company looks forward to taking a grip on its "solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country." The drug will be available in India through Cipla’s distribution network with the first batch of 1,00,000 packs that will benefit 2,00,000 patients as each pack can treat 2 patients. The Central Drugs Standards Control Organisation (CDSCO) has granted the Emergency Use Authorisation (EUA) for the usage of the cocktail. It has also received a EUA in the US and several EU countries. Note : This vdo is only for information.